Preventing untimely death in patients with peripheral artery disease (PAD) requires a detailed understanding of the predominant causes of death (COD). This literature review aims to describe how short- and long-term COD are reported in patients who had surgery for PAD.
Methods
A literature review was conducted according to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines for articles reporting specific causes of mortality in patients who had surgery for all stages of PAD. Articles were included if they reported COD after open surgical or endovascular revascularisation, or major or minor amputation for PAD. Critical appraisals were conducted according to included study types, using the Joanna Briggs Institute tools.
Results
Cause of death was reported in 21 publications. Twenty were observational and one was a randomised control trial. Study size ranged from 25 to 10,505 patients. Cardiovascular disease was the most prevalent COD in perioperative periods (42.5% from 13 studies). Long-term follow-up ranged from 1 month and 7 years with 15 studies reporting cardiac related mortality as the most frequent cause of death. However, mortality from neoplasia, respiratory disease (including pneumonia and pulmonary emboli), stroke and sepsis were prevalent. Many studies were low-average quality, with few population-based observational studies.
Conclusion
Whilst cardiovascular COD are the most prevalent reasons for mortality in patients with PAD, the proportion of patients dying from neoplasia and respiratory disease is high. Improved reporting standards for COD in studies examining PAD are needed.
FowkesFGRRudanDRudanI, et al.Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet2013; 382(9901): 1329–1340.
2.
WoelkVSpeckPKaambwaB, et al.Incidence and causes of early unplanned readmission after hospitalisation with peripheral arterial disease in Australia and New Zealand. Med J Aust2022; 216(2): 80–86.
3.
MuellerTHinterreiterFLuftC, et al.Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes. J Vasc Surg2014; 59(5): 1291–1299.
4.
NorgrenLHiattWRDormandyJATASC II Working Group, et al.Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg2007; 45(Suppl): S5–67.
5.
AgnelliGBelchJJFBaumgartnerI, et al.Morbidity and mortality associated with atherosclerotic peripheral artery disease: a systematic review. Atherosclerosis2020; 293: 94–100.
6.
IshiharaTIidaOTosakaA, et al.Severity of coronary artery disease affects prognosis of patients with peripheral artery disease. Angiology2013; 64(6): 417–422.
7.
ConteMSBradburyAWKolhP, et al.Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg2019; 58(1): S1–S109.
8.
EslamiMHSaadeddinZRybinDV, et al.Association of frailty index with perioperative mortality and in-hospital morbidity after elective lower extremity bypass. J Vasc Surg2019; 69(3): 863–874.
9.
TakejiYYamajiKTomoiY, et al.Impact of frailty on clinical outcomes in patients with critical limb ischemia. Circ Cardiovasc Interv2018; 11(7): e006778.
10.
AitkenSJLujicSRandallDA, et al.Predicting outcomes in older patients undergoing vascular surgery using the Hospital Frailty Risk Score. Br J Surg2021; 108: 659–666.
11.
EikelboomJWConnollySJBoschJ, et al.Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med Overseas Ed2017; 377(14): 1319–1330.
12.
FloresELewingerJPRoweVL, et al.Increased risk of mortality after lower extremity bypass in individuals with acute kidney injury in the Vascular Quality Initiative. J Vasc Surg2017; 65(4): 1055–1061.
13.
KechagiasAYlönenKBiancariF. Long-term outcome after isolated endarterectomy of the femoral bifurcation. World J Surg2008; 32(1): 51–54.
14.
FukaseTDohiTKatoY, et al.Long-term clinical outcomes and cause of death after endovascular treatment for femoropopliteal artery lesions. J Cardiol2021; 77(4): 417–423.
15.
AroraSPanaichSSPatelN, et al.Impact of hospital volume on outcomes of lower extremity endovascular interventions (insights from the nationwide inpatient sample [2006 to 2011]). Am J Cardiol2015; 116(5): 791–800.
16.
PollockDPetersMDJKhalilH, et al.Recommendations for the extraction, analysis, and presentation of results in scoping reviews. JBI Evid Synth2023; 21(3): 520–532.
17.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol2021; 134: 178–189.
KleinWMvan der GraafYSeegersJ, et al.Long-term cardiovascular morbidity, mortality, and reintervention after endovascular treatment in patients with iliac artery disease: the Dutch Iliac Stent Trial Study. Radiology2004; 232(2): 491–498.
20.
GutierrezJARaoSVJonesWS, et al.Survival and causes of death among veterans with lower extremity revascularization with paclitaxel-coated devices: insights from the veterans health administration. J Am Heart Assoc2021; 10(4): e018149.
21.
InderbitziRBuettikerMEnzlerM. The long-term mobility and mortality of patients with peripheral arterial disease following bilateral amputation. Eur J Vasc Endovasc Surg2003; 26(1): 59–64.
22.
FluHCLardenoyeJHVeenEJ, et al.Morbidity and mortality caused by cardiac adverse events after revascularization for critical limb ischemia. Ann Vasc Surg2009; 23(5): 583–597.
23.
CambouJPAboyansVConstansJ, et al.Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France: the COPART Registry. Eur J Vasc Endovasc Surg2010; 39(5): 577–585.
24.
KomaiHObitsuYShigematsuH. Diabetes and old age could affect long-term patency of paramalleolar distal bypass for peripheral arterial disease in Japanese patients. Circ J2011; 75(10): 2460–2464.
25.
PulliRDorigoWPratesiG, et al.Gender-related outcomes in the endovascular treatment of infrainguinal arterial obstructive disease. J Vasc Surg2012; 55(1): 105–112.
26.
ChaarCIMakarounMSMaroneLK, et al.Impact of endovascular options on lower extremity revascularization in young patients. J Vasc Surg2012; 56(3): 703–713.
27.
SilverbergDYalonTRimonU, et al.Endovascular treatment of lower extremity ischemia in chronic renal failure patients on dialysis: early and intermediate term results. Isr Med Assoc J2013; 15(12): 734–738.
28.
SharplesAKayMSykesT, et al.Multilevel bypass grafting: is it worth it?Ann Vasc Surg2014; 28(7): 1697–1702.
29.
SogaYIidaOTakaharaM, et al.Two-year life expectancy in patients with critical limb ischemia. JACC Cardiovasc Interv2014; 7(12): 1444–1449.
30.
DavaineJMQuératJGuyomarchB, et al.Primary stenting of TASC C and D femoropopliteal lesions: results of the STELLA register at 30 months. Ann Vasc Surg2014; 28(7): 1686–1696.
31.
HuangHLJimmy JuangJMChouHH, et al.Immediate results and long-term cardiovascular outcomes of endovascular therapy in octogenarians and nonoctogenarians with peripheral arterial diseases. Clin Interv Aging2016; 11: 535–543.
32.
WickströmJEJalkanenJMVenermoM, et al.Crural Index and extensive atherosclerosis of crural vessels are associated with long-term cardiovascular mortality in patients with symptomatic peripheral artery disease. Atherosclerosis2017; 264: 44–50.
33.
PiffarettiGDorigoWOttaviPPROPATEN Italian Registry Group, et al.Results of infrainguinal revascularization with bypass surgery using a heparin-bonded graft for disabling intermittent claudication due to femoropopliteal occlusive disease. J Vasc Surg2019; 70(1): 166–174.
34.
KoTHigashitaniMUemuraY, et al.Clinical outcome and diverse risk factors for different therapeutic target locations of peripheral artery disease. J Atheroscler Thromb2020; 27(8): 769–779.
35.
ConradMFKangJCambriaRP, et al.Infrapopliteal balloon angioplasty for the treatment of chronic occlusive disease. J Vasc Surg2009; 50(4): 799–805.
36.
Brochado-NetoFCCuryMVBonadimanSS, et al.Vein bypasses to branches of pedal arteries. J Vasc Surg2012; 55(3): 746–752.
37.
HuangQGrabnerMSanchezRJ, et al.Clinical characteristics and unmet need among patients with atherosclerotic cardiovascular disease stratified by statin use. Am2016; 9(8): 434–444.
38.
KobayashiMHidaKShikataH, et al.Long term outcome of femoropopliteal bypass for claudication and critical ischemia. Asian Cardiovasc Thorac Ann2004; 12(3): 208–212.
39.
SubherwalSPatelMRKoberL, et al.Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. Eur J Prev Cardiol2015; 22(3): 317–325.
40.
CaroJMigliaccio-WalleKIshakKJ, et al.The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc Disord2005; 5: 14.
41.
SartipyFSigvantBLundinF, et al.Ten year mortality in different peripheral arterial disease stages: a population based observational study on outcome. Eur J Vasc Endovasc Surg2018; 55(4): 529–536.
42.
BavieraMBertelèVAvanziniF, et al.Peripheral arterial disease: changes in clinical outcomes and therapeutic strategies in two cohorts, from 2002 to 2008 and from 2008 to 2014. A population-based study. Eur J Prev Cardiol2018; 25(16): 1735–1743.
43.
KocharAMulderHRockholdFW, et al.Cause of death among patients with peripheral artery disease: insights from the EUCLID trial. Circ Cardiovasc Qual Outcomes2020; 13(11): e006550.
44.
KaschwichMPetersFHischkeS, et al.Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease - a health insurance claims data analysis. Vasa2020; 49(6): 493–499.
45.
TauteBMThommesSTauteR, et al.The possible risk of cancer in claudicants. Angiology2011; 62(7): 579–584.
46.
BeckerRSilviJMa FatD, et al.A method for deriving leading causes of death. Bull World Health Organ2006; 84(4): 297–304.
47.
CorriereMAKimGYByrnesME, et al.Focus group study of factors relevant to treatment decisions and experiences among patients with symptomatic peripheral artery disease. J Vasc Surg2022; 76(5): 1316–1324.
48.
ProvanceJBSpertusJADeckerC, et al.Assessing patient preferences for shared decision-making in peripheral artery disease. Circ Cardiovasc Qual Outcomes2019; 12(8): e005730.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
